Biotech Values

[DewDiligence]

FDA reviewing NVS’s Enbrel FoB:

http://www.sandoz.com/media_center/press_releases_news/global_news/2015-10-02-fda-accepts-sandoz-regulatory-submission-for-a-proposed-biosimilar-etanercept.shtml

AMGN has a US patent on Enbrel running until 2027 (#msg-69263618), but NVS thinks that patent is unenforecable (see next post).